Hisun Pharmaceutical Establishes Yunsheng Synthesis to Propel Synthetic Biology in High-End Applications
1 week ago / Read about 0 minute
Author:小编   

Recently, Hisun Pharmaceutical has announced the establishment of its wholly-owned subsidiary, Zhejiang Yunsheng Synthetic Biotechnology Co., Ltd., in Taizhou. This new venture is dedicated to the realm of synthetic biology, aiming to establish itself as a "pioneer in the industrialization of synthetic biology in China." Boasting a fermentation capacity of 3,000 cubic meters, the company is poised to commission a versatile production line with an investment of 171 million yuan. The inaugural product is anticipated to hit the market in August. Drawing on its extensive expertise in microbial technology, Hisun Pharmaceutical plans to broaden its product offerings, develop a robust technology platform, and champion the integration of synthetic biology in high-end sectors. These efforts are expected to expedite the company's strategic transformation and industrial upgradation.